CTRI/2024/08/072505尚未招募Unknown
Prediction of TKI (Tyrosine Kinase Inhibitor) resistance using ex vivo studies in CML (chronic myeloid leukemia) patients. - Nil
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •Male or female aged = 18 years
- •Diagnosis of CML: Any patient who is planned for TKI or already taking TKI
排除标准
- •Another active malignancy at the time of diagnosis
研究者
相似试验
进行中（未招募）
不适用
Prediction of response to kinase inhibitors based on protein phosphorylation profiles in tumor tissue from advanced renal cell cancer patientsEUCTR2011-006009-85-NLVU University medical center225
已完成
不适用
Prediction of response to kinase inhibitors based on protein phosphorylation profiles in tumor tissue from advanced renal cell cancer patientskidney cancerRenal cell cancer10038364NL-OMON37502Vrije Universiteit Medisch Centrum225
进行中（未招募）
不适用
Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic LeukemiaPhiladelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALL)MedDRA version: 14.1Level: LLTClassification code 10000844Term: Acute lymphoblastic leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10034877Term: Philadelphia chromosome positiveSystem Organ Class: 10022891 - InvestigationsEUCTR2010-022946-25-Outside-EU/EEAChildren's Oncology Group195
进行中（未招募）
不适用
Assessment of sensitivity and therapeutic response to next-line therapy in Chronic Myeloid Leukaemia (CML)Chronic Myeloid Leukaemia (CML)Cancer - Leukaemia - Chronic leukaemiaACTRN12610000055000Australasian Leukaemia and Lymphoma Group (ALLG)1,000
进行中（未招募）
1 期
Continuing Access to the Tyrosine Kinase Inhibitor of VEGFR-2, AG-013736 (A406) for Patients Previously Receiving AG-013736 in Clinical TrialsPatients who have been treated in previous AG-013736 oncology studiesEUCTR2005-000051-15-DEPfizer Pharma GmbH50